Table 3.
Concordance between actual treatment and blind review treatment recommendations, Group 1 (False Negative Axillary Ultrasound) and Group 2 (True Negative Axillary Ultrasound)
| Group 1 | Group 2 | p-value | ||
|---|---|---|---|---|
| Overall | Actual and #1 | 65% (40/62) | 73% (44/60) | 0.332 |
| Actual and #2 | 74% (46/62) | 62% (37/60) | 0.175 | |
| #1 and #2 | 76% (47/62) | 72% (43/60) | 0.682 | |
| ER+, Age > 50 | Actual and #1 | 58% (25/43) | 84% (37/44) | 0.009 |
| Actual and #2 | 65% (28/43) | 68% (30/44) | 0.822 | |
| #1 and #2 | 74% (32/43) | 68% (30/44) | 0.637 | |
| HER2+ | Actual and #1 | 55% (6/11) | 50% (3/6) | > 0.99 |
| Actual and #2 | 64% (7/11) | 50% (3/6) | 0.644 | |
| #1 and #2 | 64% (7/11) | 100% (6/6) | 0.237 | |
| TNBC | Actual and #1 | 67% (4/6) | 36.4% (4/11) | 0.335 |
| Actual and #2 | 100% (6/6) | 45.5% (5/11) | 0.043 | |
| #1 and #2 | 67% (4/6) | 82% (9/11) | 0.584 |
ER, estrogen receptor; TNBC, triple negative breast cancer; #1, Medical oncologist #1; #2, Medical oncologist #2